Regulyatsiya immunnoy sistemy s pomoshch'yu geneticheski «modifitsirovannykh» limfotsitov pri transplantatsii allogennykh GSK

References

[1] Carella М.А., Lerma Е., Dejana A. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998; 83: 904-9.

[2] Ljungman P., Urbano-lspizua A., Cavazzana-Calvo M. et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: de? nitions and current practice in Europe. Bone Marrow Transplant. 200Б; 37: 439-49.

[3] Ciceri F., Bonini C, Stanghellini M.T. et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TKQQ7 trial]: a non-randomised phase l-ll study. The Lancet Oncology 2009; 10(51: 489 - 500.

[4] Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation. J. Clin. Oncol. 1994; 12(8): 1710-7.

[5] 5. Le Blanc K., Frassoni F., Ball L. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86.

[6] Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4 + CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-9.

[7] Ciceri F., Labopin M., Aversa F. et al. A survey of fully-haploidentical hematopoietic stem cells transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients transplanted in remission. Blood 2008; 112: 3574-81.

RIGHTS & PERMISSIONS

Eco-Vector